Artiva Biotherapeutics (ARTV) investor relations material

Company overview and business model

• Clinical-stage biotechnology company developing off-the-shelf, allogeneic NK cell-based therapies for autoimmune diseases.

• Lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy in Phase 2a and investigator-initiated trials for B-cell driven autoimmune diseases.

• Product candidates are derived from donor cells, pre-manufactured, stored frozen, and shipped to treatment locations.

• Incorporated in Delaware in 2019, headquartered in San Diego, CA.

Financial performance and metrics

• Net tangible book value as of June 30, 2026: $347.5 million, or $7.12 per share.

• After a $100 million offering at $11.07 per share, as adjusted net tangible book value would be $444.2 million, or $7.68 per share.

• Immediate dilution to new investors estimated at $3.39 per share at the assumed offering price.

Use of proceeds and capital allocation

• Net proceeds intended for working capital and general corporate purposes, including R&D, G&A expenses, and capital expenditures.

• Management retains broad discretion over the use of funds; proceeds may be invested in short-term, interest-bearing instruments pending use.